Lorenzo Morè
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lorenzo Morè has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
- Bruno G. Frenguelli
School of Life Sciences, University of Warwick, Coventry, CV4 7AL, UK
4 shared publications - James Simon Campbell Arthur
Division of Cell Signalling and Immunology, Faculty of Life Sciences, University of Dundee
4 shared publications - Lucia Privitera
School of Life Sciences, University of Warwick, Coventry, CV4 7AL, UK
4 shared publications - Małgorzata Pietraszek
Merz Pharmaceuticals GmbH
4 shared publications - Patrizia D'ADamo
Molecular Genetics of Mental Retardation Unit, San Raffaele Institute, Via Olgettina, 58 I-20132 Milan, Italy
4 shared publications Andreas Gravius
Pharmacology, Merz Pharmaceuticals GmbH, Eckenheimer Landstrasse 100, D-60318 Frankfurt am Main, Germany
3 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by Springer Nature in Research Square
p70 ribosomal protein S6 Kinase (p70S6K) as a potential peripheral biomarker for autistic symptoms in 16p11.2 deletion and duplication syndromes
Neurodevelopmental disorders (NDDs) encompass cognitive, motor, and psychiatric manifestations that require extensive assessments spanning different clinical domains. Individuals with syndromes caused by micro-deletions and -duplications in the proximal region of 16p11.2 have increased likelihood of neurodevelopmental and mental health symptoms, as well as cardiometabolic disorder. However, considerable phenotypic variability complicates prediction of risk, disease trajectory and treatment response. The identification of biomarkers in easily accessible tissues, such as Peripheral Blood Mononuclear Cells (PBMCs), could help diagnosis and prognosis, yet remains an unmet clinical need. Converging evidence implicates dysregulation of ubiquitous signalling pathways, including ERK and mTOR cascades, in altered protein synthesis across NDDs of both idiopathic and genetic origin. Here, using a hypothesis-driven approach, we examined candidate peripheral biomarkers in individuals with 16p11.2 proximal deletion and duplication syndromes. We established increased psychopathology and cognitive deficits in individuals with 16p11.2 deletion and duplication syndromes, compared to sibling controls. Furthermore, we identified a significant reduction of p70 S6 kinase (p70S6K) levels in PBMCs across both genotypes compared to controls. Notably, the magnitude of p70S6K reduction correlated with the severity of autistic symptoms independent of CNV genotype. In contrast, MAPK3/ERK1 protein levels mirrored the gene dosage, showing increased expression in individuals with the duplication and reduced levels in those with the deletion. These findings suggest that peripheral alterations in p70S6K may relate to variation in autism‑related traits within individuals with 16p11.2 deletion and duplication syndromes, indicating that it may represent a potential biomarker of autism‑associated symptom severity in this genetically at-risk group.
- 13 November 2026
- Published by Springer Nature in Research Square
Open Accessp70 ribosomal protein S6 Kinase (p70S6K) as a potential peripheral biomarker for autistic symptoms in 16p11.2 deletion and duplication syndromes
Neurodevelopmental disorders (NDDs) encompass cognitive, motor, and psychiatric manifestations that require extensive assessments spanning different clinical domains. Individuals with syndromes caused by micro-deletions and -duplications in the proximal region of 16p11.2 have increased likelihood of neurodevelopmental and mental health symptoms, as well as cardiometabolic disorder. However, considerable phenotypic variability complicates prediction of risk, disease trajectory and treatment response. The identification of biomarkers in easily accessible tissues, such as Peripheral Blood Mononuclear Cells (PBMCs), could help diagnosis and prognosis, yet remains an unmet clinical need. Converging evidence implicates dysregulation of ubiquitous signalling pathways, including ERK and mTOR cascades, in altered protein synthesis across NDDs of both idiopathic and genetic origin. Here, using a hypothesis-driven approach, we examined candidate peripheral biomarkers in individuals with 16p11.2 proximal deletion and duplication syndromes. We established increased psychopathology and cognitive deficits in individuals with 16p11.2 deletion and duplication syndromes, compared to sibling controls. Furthermore, we identified a significant reduction of p70 S6 kinase (p70S6K) levels in PBMCs across both genotypes compared to controls. Notably, the magnitude of p70S6K reduction correlated with the severity of autistic symptoms independent of CNV genotype. In contrast, MAPK3/ERK1 protein levels mirrored the gene dosage, showing increased expression in individuals with the duplication and reduced levels in those with the deletion. These findings suggest that peripheral alterations in p70S6K may relate to variation in autism‑related traits within individuals with 16p11.2 deletion and duplication syndromes, indicating that it may represent a potential biomarker of autism‑associated symptom severity in this genetically at-risk group.
- 25 April 2025
- Published by Elsevier in Neuropharmacology
- Vol. 274, 110482
Personality disorders: A preface
- 25 April 2025
- Published by Elsevier in Neuropharmacology
- Vol. 274, 110482
Personality disorders: A preface
- Open Access
- 24 January 2025
- Published by Elsevier in Neuropharmacology
- Vol. 269, 110322
Neurobiology, molecular pathways, and environmental influences in antisocial traits and personality disorders
- 24 January 2025
- Published by Elsevier in Neuropharmacology
- Vol. 269, 110322
Open AccessNeurobiology, molecular pathways, and environmental influences in antisocial traits and personality disorders
- Open Access
- 9 August 2024
- Published by Elsevier in Neuropharmacology
- Vol. 261, 110110
MSK1 is required for the experience- and ampakine-dependent enhancement of spatial reference memory and reversal learning and for the induction of Arc and BDNF
- 9 August 2024
- Published by Elsevier in Neuropharmacology
- Vol. 261, 110110
Open AccessMSK1 is required for the experience- and ampakine-dependent enhancement of spatial reference memory and reversal learning and for the induction of Arc and BDNF
- Open Access
- 28 September 2022
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 142, 104892
Emerging roles of brain metabolism in cognitive impairment and neuropsychiatric disorders
- 28 September 2022
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 142, 104892
Open AccessEmerging roles of brain metabolism in cognitive impairment and neuropsychiatric disorders
- Open Access
- 30 August 2022
- Published by Elsevier in Neuropharmacology
- Vol. 219, 109237
CREB serine 133 is necessary for spatial cognitive flexibility and long-term potentiation
- 30 August 2022
- Published by Elsevier in Neuropharmacology
- Vol. 219, 109237
Open AccessCREB serine 133 is necessary for spatial cognitive flexibility and long-term potentiation
- Open Access
- 6 May 2020
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 40 (24) , 4644-4660
Experience Recruits MSK1 to Expand the Dynamic Range of Synapses and Enhance Cognition
Experience powerfully influences neuronal function and cognitive performance, but the cellular and molecular events underlying the experience-dependent enhancement of mental ability have remained elusive. In particular, the mechanisms that couple the external environment to the genomic changes underpinning this improvement are unknown. To address this, we have used male mice harboring an inactivating mutation of mitogen- and stress-activated protein kinase 1 (MSK1), a brain-derived neurotrophic factor (BDNF)-activated enzyme downstream of the mitogen-activated protein kinase (MAPK) pathway. We show that MSK1 is required for the full extent of experience-induced improvement of spatial memory, for the expansion of the dynamic range of synapses, exemplified by the enhancement of hippocampal long-term potentiation (LTP) and long-term depression (LTD), and for the regulation of the majority of genes influenced by enrichment. In addition, and unexpectedly, we show that experience is associated with an MSK1-dependent downregulation of key MAPK and plasticity-related genes, notably of EGR1/Zif268 and Arc/Arg3.1, suggesting the establishment of a novel genomic landscape adapted to experience. By coupling experience to homeostatic changes in gene expression MSK1, represents a prime mechanism through which the external environment has an enduring influence on gene expression, synaptic function, and cognition. SIGNIFICANCE STATEMENT Our everyday experiences strongly influence the structure and function of the brain. Positive experiences encourage the growth and development of the brain and support enhanced learning and memory and resistance to mood disorders such as anxiety. While this has been known for many years, how this occurs is not clear. Here, we show that many of the positive aspects of experience depend on an enzyme called mitogen- and stress-activated protein kinase 1 (MSK1). Using male mice with a mutation in MSK1, we show that MSK1 is necessary for the majority of gene expression changes associated with experience, extending the range over which the communication between neurons occurs, and for both the persistence of memory and the ability to learn new task rules.
- 6 May 2020
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 40 (24) , 4644-4660
Open AccessExperience Recruits MSK1 to Expand the Dynamic Range of Synapses and Enhance Cognition
Experience powerfully influences neuronal function and cognitive performance, but the cellular and molecular events underlying the experience-dependent enhancement of mental ability have remained elusive. In particular, the mechanisms that couple the external environment to the genomic changes underpinning this improvement are unknown. To address this, we have used male mice harboring an inactivating mutation of mitogen- and stress-activated protein kinase 1 (MSK1), a brain-derived neurotrophic factor (BDNF)-activated enzyme downstream of the mitogen-activated protein kinase (MAPK) pathway. We show that MSK1 is required for the full extent of experience-induced improvement of spatial memory, for the expansion of the dynamic range of synapses, exemplified by the enhancement of hippocampal long-term potentiation (LTP) and long-term depression (LTD), and for the regulation of the majority of genes influenced by enrichment. In addition, and unexpectedly, we show that experience is associated with an MSK1-dependent downregulation of key MAPK and plasticity-related genes, notably of EGR1/Zif268 and Arc/Arg3.1, suggesting the establishment of a novel genomic landscape adapted to experience. By coupling experience to homeostatic changes in gene expression MSK1, represents a prime mechanism through which the external environment has an enduring influence on gene expression, synaptic function, and cognition. SIGNIFICANCE STATEMENT Our everyday experiences strongly influence the structure and function of the brain. Positive experiences encourage the growth and development of the brain and support enhanced learning and memory and resistance to mood disorders such as anxiety. While this has been known for many years, how this occurs is not clear. Here, we show that many of the positive aspects of experience depend on an enzyme called mitogen- and stress-activated protein kinase 1 (MSK1). Using male mice with a mutation in MSK1, we show that MSK1 is necessary for the majority of gene expression changes associated with experience, extending the range over which the communication between neurons occurs, and for both the persistence of memory and the ability to learn new task rules.
- 1 April 2020
- Published by Elsevier in Behavioural Brain Research
- Vol. 383, 112515
A proteomic signature for CNS adaptations to the valence of environmental stimulation
- 1 April 2020
- Published by Elsevier in Behavioural Brain Research
- Vol. 383, 112515
A proteomic signature for CNS adaptations to the valence of environmental stimulation
- Open Access
- 1 March 2017
- Published by Elsevier in Neuroscience
- Vol. 344, 346-359
Altered fronto-striatal functions in the Gdi1-null mouse model of X-linked Intellectual Disability
- 1 March 2017
- Published by Elsevier in Neuroscience
- Vol. 344, 346-359
Open AccessAltered fronto-striatal functions in the Gdi1-null mouse model of X-linked Intellectual Disability